Isosmolar contrast media (CM) iodixanol appears to be associated with a significantly lower incidence of contrast induced nephropathy (CIN) and composite cardiovascular events compared with the low-osmolar CM iopromide in patients with chronic kidney disease (CKD) undergoing coronary angiography with or without percutaneous coronary intervention (PCI), according to a study presented during the 2008 American College of Cardiology (ACC) Scientific Sessions in Chicago.
The 208-person, prospective, randomized, double-blind, single-center study, authored by Bin Nie, MD, and colleagues from Beijing Anzhen Hospital in China, compared the renal safety, occurrence of cardiovascular adverse events and diagnostic image quality of the isosmolar CM iodixanol and the low-osmolar CM iopromide.
According to Nie and colleagues, the results indicate iso-osmolar CM iodixanol appears to have a significantly lower incidence of CIN and composite cardiovascular events compared with the low-osmolar CM iopromide in patients with CKD undergoing coronary angiography with or without PCI. Additional findings included the image quality of the two agents does not differ, they added.
The findings support the class 1A recommendation from the 2007 AHA/ACC guidelines for the management of patients with Unstable-Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) and the AHA/ACC/SCAI 2007 Update of the Guidelines for PCI, recommending the use of isosmolar contrast in patients with CKD who undergo coronary arteriography, according to the researchers.
GE partially funded the study.